CDK2-IN-50

CDK2-IN-50 is a CDK2 inhibitor (IC50 = 0.77 nM) . CDK2-IN-50 can induce G1 phase arrest, indicating that it has an effective CDK2/cyclin E targeting mechanism. CDK2-IN-50 also has a significant pro-apoptotic effect. CDK2-IN-50 can be used for the study of breast cancer[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; CDK

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Field of Research

Cancer

Smiles

O=C(NC1=CC=C(C)C=C1)C2=C(N)C3=C(S2)N=C4CCCCCC4=C3C5=CC=C(OC)C=C5

Molecular Formula

C27H27N3O2S

Molecular Weight

457.59

References & Citations

[1]Ibrahim OF, et al. CDK2 inhibitors: rationally directed discovery of a novel potent lead derived from cyclohepta[e]thieno[2,3-b]pyridine. RSC Med Chem. 2025 Jul 24.